Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Why Amgen (AMGN) Stock Is Up Today

None

Amgen (AMGN) is up 4.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a rebound after last week’s sharp selloff tied to worries about the Lp(a) drug class, with investors warming to the view that Amgen’s olpasiran program may still be differentiated. Sentiment may also be getting support from recent commercial and regulatory progress for Imdelltra, which could improve uptake.

Details:

  • A recent Wall Street note argued that Amgen’s olpasiran has a different profile than a rival Lp(a) program that disappointed earlier this month, helping calm fears that the entire category is impaired.
  • That matters because Amgen shares had dropped hard after the rival trial miss, so part of today’s move could be a relief rally as investors reassess whether the earlier reaction was too severe.
  • Amgen management also discussed the business at a major healthcare conference in mid-September, keeping attention on late-stage pipeline assets and the company’s longer-term growth setup.
  • Separately, Amgen said the FDA approved reduced monitoring time for the first two doses of Imdelltra, a label change that may make treatment logistics easier and support commercialization.
  • Sources:

    Amgen, Yahoo Finance, StockAnalysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $AMGN Insider Trading Activity

    AMGN Insider Trades

    $AMGN insiders have traded $AMGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

    Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:

    • NANCY A. GRYGIEL (SVP & CCO) has made 0 purchases and 3 sales selling 4,207 shares for an estimated $1,594,866.
    • DEREK MILLER (SVP, Human Resources) has made 0 purchases and 2 sales selling 3,890 shares for an estimated $1,565,897.
    • RACHNA KHOSLA (SVP, Business Development) has made 0 purchases and 2 sales selling 3,252 shares for an estimated $1,346,498.

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $AMGN Hedge Fund Activity

    We have seen 1,422 institutional investors add shares of $AMGN stock to their portfolio, and 1,485 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $AMGN Congressional Stock Trading

    Members of Congress have traded $AMGN stock 7 times in the past 6 months. Of those trades, 2 have been purchases and 5 have been sales.

    Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:

    To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

    $AMGN Price Targets

    Multiple analysts have issued price targets for $AMGN recently. We have seen 8 analysts offer price targets for $AMGN in the last 6 months, with a median target of $345.0.

    Here are some recent targets:

    • Terence Flynn from Morgan Stanley set a target price of $333.0 on 07/08/2026
    • Gregory Renza from Truist Securities set a target price of $340.0 on 07/07/2026
    • Carter Gould from Cantor Fitzgerald set a target price of $350.0 on 07/06/2026
    • Salim Syed from Mizuho set a target price of $303.0 on 06/16/2026
    • David Amsellem from Piper Sandler set a target price of $427.0 on 05/14/2026
    • Vamil Divan from Guggenheim set a target price of $340.0 on 05/04/2026
    • Gary Nachman from Canaccord Genuity set a target price of $366.0 on 04/21/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles